By altering the lipid composition of the tumor cell membrane, increased PUFA incorporation may led to greater membrane fluidity and reduced binding between PD-L1 and PD-1, enhancing the efficacy of pembrolizumab in humanized NSCLC immune-xenografts [97]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.